Chinese english Germany Korea


塩酸イリノテカン 化学構造式
塩酸イリノテカン;カンプト;(4S)-4α,11-ジエチル-4β-ヒドロキシ-9-[[4-(ピペリジン-1-イル)ピペリジン-1-イル]カルボニルオキシ]-1H-ピラノ[3',4':6,7]インドリジノ[1,2-b]キノリン-3,14(4H,12H)-ジオン·塩酸塩;カンプトテシン11;トポテシン;カンプトテシンII;CPT11;イリノテカン HCL;イリノテカン 塩酸塩;イリノテカン塩酸塩
Irinotecan hydrochloride
CTP-11;CPT-II;campto;CPT-11;u10144oe;U 101440E;topotecin;c666-1 Cell;Irinotecan HCI;IRINOTECAN HCL
MOL File:

塩酸イリノテカン 物理性質

融点 :
250-256°C (dec.)
沸点 :
257 °C
屈折率 :
67.7 ° (C=1, H2O)
貯蔵温度 :
Soluble in DMSO or DMF at approximately 20mg/ml. Sparingly soluble in aqueous buffers. /n
水溶解度 :
Soluble in DMSO at 100mg/ml. Soluble in water at 25mg/ml with warming
Merck :
CAS データベース:
100286-90-6(CAS DataBase Reference)
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
主な危険性  Xn
Rフレーズ  22
WGK Germany  3
RTECS 番号 DW1060750
HSコード  29399990
注意喚起語 Warning
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H302 飲み込むと有害 急性毒性、経口 4 警告 P264, P270, P301+P312, P330, P501
P264 取扱い後は皮膚をよく洗うこと。
P264 取扱い後は手や顔をよく洗うこと。
P270 この製品を使用する時に、飲食または喫煙をしないこ と。
P330 口をすすぐこと。

塩酸イリノテカン 価格 もっと(9)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01BVI1752-50
Irinotecan Hydrochloride
100286-90-6 50mg ¥23400 2018-12-26 購入
富士フイルム和光純薬株式会社(wako) W01BVI1752-250
Irinotecan Hydrochloride
100286-90-6 250mg ¥80600 2018-12-26 購入
Sigma-Aldrich Japan I1406 イリノテカン 塩酸塩 topoisomerase inhibitor
Irinotecan hydrochloride topoisomerase inhibitor
100286-90-6 250mg ¥130000 2018-12-25 購入
Sigma-Aldrich Japan I1406 イリノテカン 塩酸塩 topoisomerase inhibitor
Irinotecan hydrochloride topoisomerase inhibitor
100286-90-6 50mg ¥38700 2018-12-25 購入
富士フイルム和光純薬株式会社(wako) W01TOC2688 CPT11
CPT 11
100286-90-6 10mg ¥54000 2018-12-26 購入

塩酸イリノテカン 化学特性,用途語,生産方法


lrinotecan hydrochloride, a semi-synthetic, water soluble derivative of the potent anticancer agent camptothecin, was launched in Japan for the treatment of lung, ovarian, and cervical cancers. lrinotecan exerts its antitumor activity via inhibition of topoisomerase I, a cellular enzyme that is involved in maintaining the topographic structure of DNA during the process of translation, transcription, and mitosis. lrinotecan undergoes de-esterification in vivo to yield an active metabolite, SN-38, which is 1000-fold more potent than the parent. Although being much less toxic than camptothecin, a significant number of patients in clinical trials exhibited side effects of leukopenia, diarrhea, nauseahromiting, and alopecia. Combination therapy of irinotecan with another widely used anticancer agent, cisplatin, has been reported to be superior to either agent alone. lrinotecan is in clinical trials for gastrointestinal, breast, skin, colorectal, pancreatic cancers, mesothelioma and non-Hodgkin's lymphoma.


Yellow Crystalline Powder


Yakult Honsha (Japan)


antineoplactic;'inhibitor of topoisomerase I


A DNA topoisomerase inhibitor


ChEBI: A hydrochloride obtained by combining irinotecan with one molar equivalent of hydrochloric acid. Used (in the form of its trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancr as after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, which is ~1000 times more active.

brand name

Camptosar (Pharmacia &Upjohn) ;Topotecin.


Irinotecan is available in 100-mg or 5-mL vials for IV administrationand is used in combination with 5-FU and leucovorinas first-line treatment of metastatic colon cancer.The agent may also be used as a single agent in colorectalcancer as a second-line therapy when 5-FU therapy hasfailed. Additional uses include small cell lung cancer,NSCLC, cervical cancer, esophageal cancer, and gastric cancer Irinotecan is 30% to 60% plasma protein bound, whereasthe active metabolite SN-38 is 95% protein bound. Bindingof SN-38 as the lactone stabilizes the material to ring opening.The elimination of the agent occurs primarily in the bilewith a minor amount of renal elimination. The excretion ofactive metabolites or inactive metabolites such as the glucuronideSN-38G, which may be converted back to SN-38 inthe bile, has been associated with severe diarrhea. Irinotecanand SN-38 have half-lives of 8 and 14 hours, respectively.Irinotecan has two dose-limiting toxicities, myelosuppressionand diarrhea. The diarrhea occurs in two forms, earlyand late. The early form occurs within the first 24 hours afteradministration. It has been associated with inhibition ofacetylcholinesterase, which results in increased gut motility.This early phase is also associated with flushing, abdominalpain, and excessive sweating. Atropine can be used to relievethese symptoms but it is not recommended for prophylacticuse unless there has been a prior episode. The late-phasediarrhea occurs after 24 hours and has been associated withthe presence of active material, particularly SN-38 in the gut,and may last 3 to 10 days. The prolonged nature may lead todehydration and electrolyte imbalances. Loperamide therapyis recommended at the first appearance of a loose stool. If thediarrhea persists, additional agents may be used includingantibiotics that decrease β-glucosidase–producing bacteria inthe gut and prevent the overgrowth of pathogenic bacteria.111Other toxicities include emesis and alopecia.


Inhibitor of DNA topoisomerase I that displays antitumor activity against a range of tumor types.

塩酸イリノテカン 上流と下流の製品情報



塩酸イリノテカン 生産企業

Global( 276)Suppliers
名前 電話番号 ファックス番号 電子メール 国籍 製品カタログ 優位度
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 China 19917 60
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 CHINA 3202 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 21753 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20672 55
Mainchem Co., Ltd.
+86-0592-6210733 CHINA 32447 55
Nanjing Finetech Chemical Co., Ltd.
025-85710122 17714198479
025-85710122 CHINA 892 55
Shanghai Zheyan Biotech Co., Ltd.
18017610038 CHINA 3623 58
career henan chemical co
+86-371-86658258 CHINA 27142 58
Shaanxi Yikanglong Biotechnology Co., Ltd.
17791478691 CHINA 297 58
Chengdu Biopurify Phytochemicals Ltd.
18080483897 CHINA 2236 58


  • 100286-90-6
  • CPT 11 hydrochloride
  • c666-1 Cell
  • Camptothecin 11
  • U 101440E
  • (S)-[1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester hydrochloride
  • CTP-11
  • [1,4’-Bipiperidine]-1’-carboxylic Acid (4S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3’,4’:6,7]indolizino[1,2-b]quinolin-9-yl Ester Hydrochloride Trihydrate
  • irinotecan hydrochloride (anhydrous)
  • irinotecan hydrochloirde
  • Irinotecan hydrochloride, 98%, from camptothecin
  • Irrotecan hydrochloride
  • Irinotecan hydrochloride (S)-[1,4'-Bipiperidine]-1'-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester hydrochloride
  • (S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-9-yl ester monohydrochloride trihydrate
  • Camptothecin II
  • CPT-II
  • [1,4′-Bipiperidine]-1′-carboxylic acid, CPT-11,(S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl ester
  • (4S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl[1,4'-bipiperidine]-1'-carboxylicacidesterhydrochloride
  • (S)-4,11-Diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl ester
  • Irinotecan hydrochloride(CPT-11)
  • Irinotecan HCI
  • Irinotecan-D10 HCl
  • roxy-3,4-dioxo-1h-pyrano(3’,4’:6,7)indolizino(1,2-b)quinolin-9-ylester,monoh
  • topotecin
  • u10144oe
  • (1,4’-bipiperidine)-1’-carboxylicacid,3,4,12,14-tetrahydro-4,11-diethyl-4-hyd
  • (s)-ydrochlorid
  • 7-ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxycamptothecinhydrochlor
  • campto
  • 塩酸イリノテカン
  • カンプト
  • (4S)-4α,11-ジエチル-4β-ヒドロキシ-9-[[4-(ピペリジン-1-イル)ピペリジン-1-イル]カルボニルオキシ]-1H-ピラノ[3',4':6,7]インドリジノ[1,2-b]キノリン-3,14(4H,12H)-ジオン·塩酸塩
  • カンプトテシン11
  • トポテシン
  • カンプトテシンII
  • CPT11
  • イリノテカン HCL
  • イリノテカン 塩酸塩
  • イリノテカン塩酸塩
  • 生化学
  • 試験研究用抗腫瘍剤
  • 酵素阻害剤
  • 抗腫瘍薬
Copyright 2017 © ChemicalBook. All rights reserved